Eckert & Ziegler

History

Year	Detail
1992	BEBIG Isotopentechnik und Umweltdiagnostik GmbH (BEBIG GmbH) was founded by Dr. Andreas Eckert and Jürgen Ziegler for the manufacturing of weak sources of radiation for industrial and medical purposes.
1999	Eckert & Ziegler AG acquired Isotope Products Laboratories (IPL) Inc., thereby significantly expanding its development and production of radioactive sources for medical (like brachytherapy seeds for cancer), industrial (radiometry, quality assurance), and scientific uses, integrating IPL's expertise in manufacturing calibration sources and sealed sources into its global portfolio.
2000	Eckert & Ziegler AG acquired the worldwide sources business from DuPont Pharmaceuticals Co. This acquisition increased Eckert & Ziegler's global market share in nuclear medicine reference sources from 30% to over 65%.
2004	The company acquired MMI, the radiation product business of HEK GmbH, Lübeck. This acquisition was a strategic move, integrating the target company's expertise in radiation products into the acquiring entity's portfolio.
2009	Eckert & Ziegler acquired tNuclitec GmbH, the German isotope specialist based in Braunschweig, for $8.5 million. This strategic move expanded EZAG's isotope technology expertise, integrating Nuclitec (currently Eckert & Ziegler Nuclitec GmbH) as a key part of its global operations, boosting its capabilities in isotope products and measurement services.
2010	Eckert & Ziegler increased its stake in the Belgian company IBt (International Brachytherapy S.A.) to approximately 72% (specifically 71.9%) in 2010 through a mandatory takeover bid.
2011	Eckert & Ziegler Strahlen- und Medizintechnik AG, a company specializing in radioactive pharmaceuticals and their production technology, entered into an agreement with Bioscan Inc. to acquire its radiopharmaceutical equipment business.
2016	Eckert & Ziegler BEBIG SA acquired 100% of BrachySolutions BVBA, taking over the Belgian provider of brachytherapy accessories to expand its portfolio and capabilities in the cancer treatment market, integrating them into its growing global medical device business.
2022	Eckert & Ziegler acquired Argentine nuclear medicine specialist Tecnonuclear S.A., expanding its South American footprint and access to the SPECT diagnostics market by incorporating Tecnonuclear's expertise in technetium-99 generators and related biomolecules.